Stock listing
ZNTL Stock Price, News, Filings & Events — Zentalis Pharmaceuticals, Inc.
Selected listing: ZNTL · NASDAQ · USD · US
This page tracks Zentalis Pharmaceuticals, Inc.'s ZNTL:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ZNTL:NASDAQ. ZNTL:NASDAQ is the stock-level entry point for investors researching Zentalis Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Zentalis Pharmaceuticals, Inc. is a public company traded under the ticker ZNTL in the American market. The company has a market capitalization of approximately $347.4 million. Zentalis focuses on developing innovative therapies for cancer treatment.
- Ticker
- ZNTL:NASDAQ
- Asset type
- Stock
- Market cap
- $332.3M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Zentalis Pharmaceuticals, Inc. ZNTL:NASDAQ stock context
This page tracks Zentalis Pharmaceuticals, Inc.'s ZNTL:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ZNTL:NASDAQ. ZNTL:NASDAQ is the stock-level entry point for investors researching Zentalis Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Zentalis Pharmaceuticals, Inc. is a public company traded under the ticker ZNTL in the American market. The company has a market capitalization of approximately $347.4 million. Zentalis focuses on developing innovative therapies for cancer treatment.
Latest news from Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase A...
August 18, 2026
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase A...
August 17, 2026
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
August 13, 2026
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
August 13, 2026
Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates
August 6, 2026
Research Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. investor report
Review AI stock analysis and investor report context for ZNTL:NASDAQ.
Zentalis Pharmaceuticals, Inc. company profile
View the public company page for Zentalis Pharmaceuticals, Inc. on 6ix.
Zentalis Pharmaceuticals, Inc. news
Read company news and market updates connected to Zentalis Pharmaceuticals, Inc..
Zentalis Pharmaceuticals, Inc. investor events
Find investor webinars, events, and replay context for Zentalis Pharmaceuticals, Inc..